NCT00616109View on ClinicalTrials.gov

Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

December 31, 2009

Study Completion Date

January 31, 2011

Conditions
Extensive-Stage Small Cell Lung Cancer
Interventions
DRUG

sunitinib

Sunitinib will be given at 50 mg/day as a single agent for 4 consecutive weeks followed by a 2-week rest period to form a complete cycle of 6 weeks.

Trial Locations (1)

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER

NCT00616109 - Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC | Biotech Hunter | Biotech Hunter